Allogene Therapeutics, Inc. Payments for Leasing Costs, Commissions, and Tenant Improvements
Allogene Therapeutics, Inc. (ALLO) reported Payments for Leasing Costs, Commissions, and Tenant Improvements of $6.53 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements · last filed 2026-08-12
- Allogene Therapeutics, Inc. payments for leasing costs, commissions, and tenant improvements for the quarter ending 2026-06-30 was $3.29M, a 0.12% increase year-over-year.
- Allogene Therapeutics, Inc. payments for leasing costs, commissions, and tenant improvements for the quarter ending 2026-03-31 was $3.23M, a 0.19% increase year-over-year.
- Allogene Therapeutics, Inc. payments for leasing costs, commissions, and tenant improvements for the quarter ending 2025-12-31 was $3.24M, a 1.22% increase year-over-year.
- Allogene Therapeutics, Inc. payments for leasing costs, commissions, and tenant improvements for the quarter ending 2025-09-30 was $3.17M, a 1.02% increase year-over-year.
- Allogene Therapeutics, Inc. payments for leasing costs, commissions, and tenant improvements for fiscal 2025 was $12.92M, a 3.33% increase from fiscal 2024.
- Allogene Therapeutics, Inc. payments for leasing costs, commissions, and tenant improvements for fiscal 2024 was $12.51M, a 3.78% increase from fiscal 2023.
- Allogene Therapeutics, Inc. payments for leasing costs, commissions, and tenant improvements for fiscal 2023 was $12.05M, a 26.30% increase from fiscal 2022.
- Allogene Therapeutics, Inc. payments for leasing costs, commissions, and tenant improvements for fiscal 2022 was $9.54M, a 58.66% increase from fiscal 2021.
| Period end | Payments for Leasing Costs, Commissions, and Tenant Improvements 1 month | Payments for Leasing Costs, Commissions, and Tenant Improvements 3 month | Payments for Leasing Costs, Commissions, and Tenant Improvements 6 month | Payments for Leasing Costs, Commissions, and Tenant Improvements 9 month | Payments for Leasing Costs, Commissions, and Tenant Improvements 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $3.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $6.53M 10-Q · filed 2026-08-12 | $9.76M derived: sum of 3 quarters · filed 2026-08-12 | $12.93M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $3.23M 10-Q · filed 2026-05-13 | $6.47M derived: sum of 2 quarters · filed 2026-05-13 | $9.64M derived: sum of 3 quarters · filed 2026-05-13 | $12.93M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $3.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $6.40M derived: sum of 2 quarters · filed 2026-03-12 | $9.69M derived: sum of 3 quarters · filed 2026-08-12 | $12.92M 10-K · filed 2026-03-12 | |
| 2025-09-30 | $3.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $6.46M derived: sum of 2 quarters · filed 2026-08-12 | $9.69M 10-Q · filed 2025-11-06 | $12.88M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | $3.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $6.52M 10-Q · filed 2026-08-12 | $9.71M derived: sum of 3 quarters · filed 2026-08-12 | $12.85M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | $3.23M 10-Q · filed 2026-05-13 | $6.42M derived: sum of 2 quarters · filed 2026-05-13 | $9.56M derived: sum of 3 quarters · filed 2026-05-13 | $12.66M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $6.33M derived: sum of 2 quarters · filed 2026-03-12 | $9.44M derived: sum of 3 quarters · filed 2026-03-12 | $12.51M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $3.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $6.24M derived: sum of 2 quarters · filed 2025-11-06 | $9.31M 10-Q · filed 2025-11-06 | $12.34M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $3.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $6.17M 10-Q · filed 2025-08-13 | $9.21M derived: sum of 3 quarters · filed 2025-08-13 | $12.23M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $3.07M 10-Q · filed 2025-05-13 | $6.10M derived: sum of 2 quarters · filed 2025-05-13 | $9.13M derived: sum of 3 quarters · filed 2025-05-13 | $12.15M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $3.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $6.06M derived: sum of 2 quarters · filed 2025-03-13 | $9.08M derived: sum of 3 quarters · filed 2025-03-13 | $12.05M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $3.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $6.05M derived: sum of 2 quarters · filed 2024-11-07 | $9.01M 10-Q · filed 2024-11-07 | $11.95M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $3.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $5.99M 10-Q · filed 2024-08-07 | $8.92M derived: sum of 3 quarters · filed 2024-08-07 | $11.55M derived: sum of 4 quarters · filed 2024-08-07 | |
| 2023-03-31 | $2.96M 10-Q · filed 2024-05-13 | $5.90M derived: sum of 2 quarters · filed 2024-05-13 | $8.52M derived: sum of 3 quarters · filed 2024-05-13 | $10.53M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | $2.94M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $5.56M derived: sum of 2 quarters · filed 2024-03-14 | $7.56M derived: sum of 3 quarters · filed 2024-03-14 | $9.54M 10-K/A · filed 2024-03-14 | |
| 2022-09-30 | $2.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $4.63M derived: sum of 2 quarters · filed 2023-11-02 | $6.61M 10-Q · filed 2023-11-02 | $8.56M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $3.98M 10-Q · filed 2023-08-02 | $5.94M derived: sum of 3 quarters · filed 2024-03-14 | $7.56M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-03-31 | $1.98M 10-Q · filed 2023-05-03 | $3.94M derived: sum of 2 quarters · filed 2024-03-14 | $5.56M derived: sum of 3 quarters · filed 2024-03-14 | $7.03M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-12-31 | $1.96M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $3.58M derived: sum of 2 quarters · filed 2024-03-14 | $5.05M derived: sum of 3 quarters · filed 2024-03-14 | $6.01M 10-K/A · filed 2024-03-14 | |
| 2021-09-30 | $1.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $3.09M derived: sum of 2 quarters · filed 2022-11-02 | $4.06M 10-Q · filed 2022-11-02 | $6.07M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-06-30 | $1.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $2.43M 10-Q · filed 2022-08-09 | $4.44M derived: sum of 3 quarters · filed 2024-03-14 | $5.86M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-03-31 | $966.00K 10-Q · filed 2022-05-04 | $2.97M derived: sum of 2 quarters · filed 2024-03-14 | $4.39M derived: sum of 3 quarters · filed 2024-03-14 | $5.81M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2020-12-31 | $2.01M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $3.43M derived: sum of 2 quarters · filed 2024-03-14 | $4.85M derived: sum of 3 quarters · filed 2024-03-14 | $6.24M 10-K/A · filed 2024-03-14 | |
| 2020-09-30 | $1.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $2.84M derived: sum of 2 quarters · filed 2021-11-04 | $4.24M 10-Q · filed 2021-11-04 | $5.62M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2020-06-30 | $1.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $2.82M 10-Q · filed 2021-08-04 | $4.20M derived: sum of 3 quarters · filed 2022-02-23 | $5.22M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2020-03-31 | $1.40M 10-Q · filed 2021-05-05 | $2.78M derived: sum of 2 quarters · filed 2022-02-23 | $3.80M derived: sum of 3 quarters · filed 2022-02-23 | $4.57M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2019-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $2.41M derived: sum of 2 quarters · filed 2022-02-23 | $3.17M derived: sum of 3 quarters · filed 2022-02-23 | $3.56M 10-K · filed 2022-02-23 | |
| 2019-09-30 | $1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $1.79M derived: sum of 2 quarters · filed 2020-11-04 | $2.18M 10-Q · filed 2020-11-04 | $2.21M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | $765.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $1.16M 10-Q · filed 2020-08-05 | $1.19M derived: sum of 3 quarters · filed 2021-02-25 | $1.19M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | $391.00K 10-Q · filed 2020-05-06 | $422.00K derived: sum of 2 quarters · filed 2021-02-25 | $422.00K derived: sum of 3 quarters · filed 2021-02-25 | $422.00K derived: sum of 4 quarters · filed 2021-02-25 | |
| 2018-12-31 | $31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $31.00K derived: sum of 2 quarters · filed 2021-02-25 | $31.00K derived: sum of 3 quarters · filed 2021-02-25 | $31.00K 10-K · filed 2021-02-25 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $0.00 derived: sum of 2 quarters · filed 2019-11-05 | $0.00 10-Q · filed 2019-11-05 | ||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $0.00 10-Q · filed 2019-08-07 | |||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-07 | ||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |